GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
BlackRock Latin American Investment Trust announces a 4.92 cents per share dividend, payable 7 Feb 2025. Secure your shares by 10 Jan 2025 to be eligible...
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
BlackRock Latin American Investment Trust announces a 4.92 cents per share dividend, payable 7 Feb 2025. Secure your shares by 10 Jan 2025 to be eligible...